22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › REVOLUTION MEDICINES INC. › 2024-2025

REVOLUTION MEDICINES INC. 2024-2025 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and REVOLUTION MEDICINES INC.’s Form 8-K, filed June 27, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 6Ballot items
  • 285Asset managers, any item
  • 2,315Fund votes
  • June 26, 2025Meeting date

Results at a glance

Meeting of June 26, 2025: 6 items on REVOLUTION MEDICINES INC.’s Form 8-K, filed June 27, 2025: 2 approved · 4 passed (calculated).

Dissent

Notable dissent: 3 directors (19.1%, 14.5%, 14.5% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore REVOLUTION MEDICINES INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by REVOLUTION MEDICINES INC.

These tallies are REVOLUTION MEDICINES INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 27, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

REVOLUTION MEDICINES INC. — official shareholder meeting results, meeting held June 26, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Frank K. Clyburn, Jr. 147,380,169---- 512,89810,241,664 99.7%Passed (calculated)—
Elect Director: Sandra J. Horning, M.D. 126,395,644---- 21,497,42310,241,664 85%Passed (calculated)—
Elect Director: Sushil Patel, Ph.D. 126,396,068---- 21,496,99910,241,664 85%Passed (calculated)—
Elect Director: Thilo Schroeder, Ph.D. 119,696,091---- 28,196,97610,241,664 81%Passed (calculated)—
2. The appointment, by the audit committee of the Company's board of directors, of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2025 157,875,830214,96343,938 ---- 99.9%Approved—
3. On a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, pursuant to the compensation disclosure rules of the SEC 145,265,8252,597,92029,322 --10,241,664 98%Approved—

Source: REVOLUTION MEDICINES INC., Form 8-K, filed with the SEC on June 27, 2025 — read the filing on EDGAR.

How asset managers voted at the REVOLUTION MEDICINES INC. 2024-2025 meeting

285 asset managers disclosed a vote on at least one REVOLUTION MEDICINES INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Frank K. Clyburn, Jr.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 6 wordings of this item as funds reported it.

99.7% Majority: yes · of votes cast

FOR 99.7%
FOR: 147,380,169WITHHELD: 512,898
Details: description as filed, official tally, votes by 84 asset managers

Description as filed by funds: To elect four Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until his or her successor is elected: Frank K. Clyburn, Jr.

REVOLUTION MEDICINES INC.’s own tally for this item (“Elect Director: Frank K. Clyburn, Jr.”): 147,380,169 for, 512,898 withheld, per its Form 8-K filed June 27, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 99.7% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 84 asset managers below reported 61,984,533 for, 15,382 withheld, 0 abstained, 87 not voted.

FOR
FOR: 61,984,533ABSTAIN: 0WITHHOLD: 15,382NOT VOTED: 87
Largest asset managers voting on “To elect four Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until his or ” at REVOLUTION MEDICINES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard22,155,7860 00For
Fidelity9,184,2980 00For
T. Rowe Price5,370,4410 00For
BlackRock5,206,0440 00For
JANUS INVESTMENT FUND4,687,6720 00For
JPMorgan2,073,8150 00For
State Street1,992,0230 00For
Charles Schwab1,964,9330 00For
Manager Directed Portfolios956,3810 00For
Equitable632,0500 00For
American Century612,3580 00For
Hartford502,6460 00For
Jackson National489,3220 00For
Goldman Sachs462,9750 00For
TIAA453,9460 00For
MUTUAL FUND SERIES TRUST372,2290 00For
Columbia Threadneedle368,2550 00For
Victory Capital359,7080 00For
HARBOR FUNDS342,0090 00For
QUANTITATIVE MASTER SERIES LLC292,9340 00For
Voya292,6490 00For
Bridge Builder Trust287,3030 00For
John Hancock267,5670 00For
AIG/SunAmerica253,4810 00For
Lincoln Financial180,3410 00For

Showing the 25 largest of 84 asset managers. All 84 are in the interactive database (link above).

Elect Director: Sandra J. Horning, M.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 6 wordings of this item as funds reported it.

85% Majority: yes · of votes cast

FOR 85%WITHHELD
FOR: 126,395,644WITHHELD: 21,497,423
Details: description as filed, official tally, votes by 84 asset managers

Description as filed by funds: To elect four Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until his or her successor is elected: Sandra J. Horning, M.D.

REVOLUTION MEDICINES INC.’s own tally for this item (“Elect Director: Sandra J. Horning, M.D.”): 126,395,644 for, 21,497,423 withheld, per its Form 8-K filed June 27, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 85% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 84 asset managers below reported 59,022,889 for, 2,070,239 withheld, 906,788 abstained, 87 not voted.

FOR
FOR: 59,022,889ABSTAIN: 906,788WITHHOLD: 2,070,239NOT VOTED: 87
Largest asset managers voting on “To elect four Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until his or ” at REVOLUTION MEDICINES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard22,155,7860 00For
Fidelity9,184,2980 00For
T. Rowe Price5,370,4410 00For
BlackRock5,206,0440 00For
JANUS INVESTMENT FUND4,687,6720 00For
JPMorgan2,073,8150 00For
State Street1,979,2820 012,741For
Charles Schwab1,964,9330 00For
Manager Directed Portfolios956,3810 00For
Equitable441,4220 0190,628Mixed
American Century00 0612,358Withhold
Hartford502,6460 00For
Jackson National374,7530 114,5690Mixed
Goldman Sachs429,4050 033,570Mixed
TIAA453,9460 00For
MUTUAL FUND SERIES TRUST372,2290 00For
Columbia Threadneedle368,2550 00For
Victory Capital1,6070 0358,101Withhold
HARBOR FUNDS00 342,0090Abstain
QUANTITATIVE MASTER SERIES LLC292,9340 00For
Voya292,6490 00For
Bridge Builder Trust50,2310 237,0720Mixed
John Hancock95,9320 171,6350Mixed
AIG/SunAmerica00 0253,481Withhold
Lincoln Financial180,3410 00For

Showing the 25 largest of 84 asset managers. All 84 are in the interactive database (link above).

Elect Director: Sushil Patel, Ph.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 6 wordings of this item as funds reported it.

85% Majority: yes · of votes cast

FOR 85%WITHHELD
FOR: 126,396,068WITHHELD: 21,496,999
Details: description as filed, official tally, votes by 84 asset managers

Description as filed by funds: To elect four Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until his or her successor is elected: Sushil Patel, Ph.D.

REVOLUTION MEDICINES INC.’s own tally for this item (“Elect Director: Sushil Patel, Ph.D.”): 126,396,068 for, 21,496,999 withheld, per its Form 8-K filed June 27, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 85% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 84 asset managers below reported 59,022,889 for, 2,070,239 withheld, 906,788 abstained, 87 not voted.

FOR
FOR: 59,022,889ABSTAIN: 906,788WITHHOLD: 2,070,239NOT VOTED: 87
Largest asset managers voting on “To elect four Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until his or ” at REVOLUTION MEDICINES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard22,155,7860 00For
Fidelity9,184,2980 00For
T. Rowe Price5,370,4410 00For
BlackRock5,206,0440 00For
JANUS INVESTMENT FUND4,687,6720 00For
JPMorgan2,073,8150 00For
State Street1,979,2820 012,741For
Charles Schwab1,964,9330 00For
Manager Directed Portfolios956,3810 00For
Equitable441,4220 0190,628Mixed
American Century00 0612,358Withhold
Hartford502,6460 00For
Jackson National374,7530 114,5690Mixed
Goldman Sachs429,4050 033,570Mixed
TIAA453,9460 00For
MUTUAL FUND SERIES TRUST372,2290 00For
Columbia Threadneedle368,2550 00For
Victory Capital1,6070 0358,101Withhold
HARBOR FUNDS00 342,0090Abstain
QUANTITATIVE MASTER SERIES LLC292,9340 00For
Voya292,6490 00For
Bridge Builder Trust50,2310 237,0720Mixed
John Hancock95,9320 171,6350Mixed
AIG/SunAmerica00 0253,481Withhold
Lincoln Financial180,3410 00For

Showing the 25 largest of 84 asset managers. All 84 are in the interactive database (link above).

Elect Director: Thilo Schroeder, Ph.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 6 wordings of this item as funds reported it.

81% Majority: yes · of votes cast

FOR 81%WITHHELD
FOR: 119,696,091WITHHELD: 28,196,976
Details: description as filed, official tally, votes by 84 asset managers

Description as filed by funds: To elect four Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until his or her successor is elected: Thilo Schroeder, Ph.D.

REVOLUTION MEDICINES INC.’s own tally for this item (“Elect Director: Thilo Schroeder, Ph.D.”): 119,696,091 for, 28,196,976 withheld, per its Form 8-K filed June 27, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 81% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 84 asset managers below reported 56,828,372 for, 4,264,755 withheld, 906,788 abstained, 87 not voted.

FOR
FOR: 56,828,372ABSTAIN: 906,788WITHHOLD: 4,264,755NOT VOTED: 87
Largest asset managers voting on “To elect four Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until his or ” at REVOLUTION MEDICINES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard22,155,7860 00For
Fidelity9,184,2980 00For
T. Rowe Price5,370,4410 00For
BlackRock5,206,0440 00For
JANUS INVESTMENT FUND4,687,6720 00For
JPMorgan2,073,8150 00For
State Street5,6680 01,986,355Withhold
Charles Schwab1,964,9330 00For
Manager Directed Portfolios956,3810 00For
Equitable441,4220 0190,628Mixed
American Century00 0612,358Withhold
Hartford502,6460 00For
Jackson National374,7530 114,5690Mixed
Goldman Sachs429,4050 033,570Mixed
TIAA453,9460 00For
MUTUAL FUND SERIES TRUST372,2290 00For
Columbia Threadneedle368,2550 00For
Victory Capital1,6070 0358,101Withhold
HARBOR FUNDS00 342,0090Abstain
QUANTITATIVE MASTER SERIES LLC292,9340 00For
Voya292,6490 00For
Bridge Builder Trust50,2310 237,0720Mixed
John Hancock95,9320 171,6350Mixed
AIG/SunAmerica00 0253,481Withhold
Lincoln Financial54,5290 0125,812Mixed

Showing the 25 largest of 84 asset managers. All 84 are in the interactive database (link above).

On a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy…

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 18 wordings of this item as funds reported it.

98% Approved · of votes cast

FOR 98%
FOR: 145,265,825AGAINST: 2,597,920

Prior year: 98.8% for (June 19, 2024 meeting) ▼ 0.5 pts

Details: description as filed, official tally, votes by 285 asset managers

Description as filed by funds: TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS AS DISCLOSED IN THE PROXY STATEMENT PURSUANT TO THE COMPENSATION DISCLOSURE RULES OF THE SECURITIES AND EXCHANGE COMMISSION ("SAY-ON-PAY").

REVOLUTION MEDICINES INC.’s own tally for this item (“3. On a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, pursuant to the compensation disclosure rules of the SEC”): 145,265,825 for, 2,597,920 against — passed, per its Form 8-K filed June 27, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, pursuant to the compensation disclosure rules of the SEC.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 84 asset managers voting on “TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS AS DI” at REVOLUTION MEDICINES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard22,155,7860 00For
Fidelity9,184,2980 00For
T. Rowe Price5,370,4410 00For
BlackRock5,206,0440 00For
JANUS INVESTMENT FUND4,687,6720 00For
JPMorgan2,073,8150 00For
State Street1,991,466557 00For
Charles Schwab1,964,9330 00For
Manager Directed Portfolios956,3810 00For
Equitable632,0500 00For
American Century0612,358 00Against
Hartford502,6460 00For
Jackson National489,3220 00For
Goldman Sachs462,9750 00For
TIAA453,9460 00For
MUTUAL FUND SERIES TRUST372,2290 00For
Columbia Threadneedle368,2550 00For
Victory Capital359,7080 00For
HARBOR FUNDS342,0090 00For
QUANTITATIVE MASTER SERIES LLC292,9340 00For
Voya292,6490 00For
Bridge Builder Trust287,3030 00For
John Hancock267,5670 00For
AIG/SunAmerica253,4810 00For
Lincoln Financial180,3410 00For

Fund voting reports, all 84 managers: 61,143,551 for, 845,612 against, 10,752 abstained, 87 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 224 asset managers voting on “TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS AS DI” at REVOLUTION MEDICINES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
FARALLON CAPITAL MANAGEMENT LLC12,680,5700 00For
Wellington9,611,5080 00For
Fidelity7,859,8120 00For
Janus Henderson7,773,1190 00For
T. Rowe Price7,601,7950 00For
BlackRock5,798,00430,757 00For
State Street5,269,753557 00For
BVF INC/IL4,982,3840 00For
GEODE CAPITAL MANAGEMENT, LLC4,178,8160 00For
GV Management Company, L.L.C.4,080,7000 00For
Holocene Advisors, LP4,012,4570 00For
Woodline Partners LP3,453,6830 00For
Paradigm Biocapital Advisors LP3,388,9950 00For
DEERFIELD MANAGEMENT COMPANY, L.P.3,384,0720 00For
JPMorgan3,213,6320 00For
AH Capital Management, L.L.C.2,748,5230 00For
Charles Schwab1,989,9510 00For
Hood River Capital Management LLC1,664,1620 00For
Casdin Capital, LLC1,277,4630 00For
Northern Trust1,266,1720 00For
AMERIPRISE FINANCIAL INC1,144,2880 00For
WESTFIELD CAPITAL MANAGEMENT CO LP1,019,40740,210 00For
Frazier Life Sciences Management, L.P.997,4550 00For
MELLON INVESTMENTS Corp731,8580 00For
PICTET ASSET MANAGEMENT SA710,6670 00For

Institutional-manager reports, all 224 managers: 110,860,394 for, 1,853,989 against, 15,652 abstained, 2,931 not voted, 226,000 unknown. Showing the 25 largest; every one is in the interactive database (link above).

The appointment, by the audit committee of the Company's board of directors, of PricewaterhouseCoopers LLP as the…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 4 wordings of this item as funds reported it.

99.9% Approved · of votes cast

FOR 99.9%
FOR: 157,875,830AGAINST: 214,963

Prior year: 100.0% for (June 19, 2024 meeting) ▼ 0.1 pts

Details: description as filed, official tally, votes by 84 asset managers

Description as filed by funds: To ratify the appointment, by the Audit Committee of the Company's Board of Directors, of PricewaterhouseCoopers LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025; and

REVOLUTION MEDICINES INC.’s own tally for this item (“2. The appointment, by the audit committee of the Company's board of directors, of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 20”): 157,875,830 for, 214,963 against — passed, per its Form 8-K filed June 27, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the appointment, by the audit committee of the Company's board of directors, of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2025.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 84 asset managers below reported 61,988,311 for, 852 against, 10,752 abstained, 87 not voted.

FOR
FOR: 61,988,311AGAINST: 852ABSTAIN: 10,752NOT VOTED: 87
Largest asset managers voting on “To ratify the appointment, by the Audit Committee of the Company's Board of Directors, of PricewaterhouseCoope” at REVOLUTION MEDICINES INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard22,155,7860 00For
Fidelity9,184,2980 00For
T. Rowe Price5,370,4410 00For
BlackRock5,206,0440 00For
JANUS INVESTMENT FUND4,687,6720 00For
JPMorgan2,073,8150 00For
State Street1,991,908115 00For
Charles Schwab1,964,9330 00For
Manager Directed Portfolios956,3810 00For
Equitable632,0500 00For
American Century612,3580 00For
Hartford502,6460 00For
Jackson National489,3220 00For
Goldman Sachs462,9750 00For
TIAA453,9460 00For
MUTUAL FUND SERIES TRUST372,2290 00For
Columbia Threadneedle368,2550 00For
Victory Capital359,7080 00For
HARBOR FUNDS342,0090 00For
QUANTITATIVE MASTER SERIES LLC292,9340 00For
Voya292,6490 00For
Bridge Builder Trust287,3030 00For
John Hancock267,5670 00For
AIG/SunAmerica253,4810 00For
Lincoln Financial180,3410 00For

Showing the 25 largest of 84 asset managers. All 84 are in the interactive database (link above).

Largest REVOLUTION MEDICINES INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 186,258,206 shares outstanding at the time of that meeting.

Fund voting reports: top REVOLUTION MEDICINES INC. shareholders by shares voted on “TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE…”, 2024-2025
#Asset manager % of shares outstanding
1Vanguard 11.90%
2Fidelity 4.93%
3T. Rowe Price 2.88%
4BlackRock 2.80%
5JANUS INVESTMENT FUND 2.52%
6JPMorgan 1.11%
7State Street 1.07%
8Charles Schwab 1.05%
9Manager Directed Portfolios 0.51%
10Equitable 0.34%
Institutional-manager reports: top REVOLUTION MEDICINES INC. shareholders by shares voted on “TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE…”, 2024-2025
#Asset manager % of shares outstanding
1FARALLON CAPITAL MANAGEMENT LLC 6.81%
2Wellington 5.16%
3Fidelity 4.22%
4Janus Henderson 4.17%
5T. Rowe Price 4.08%
6BlackRock 3.13%
7State Street 2.83%
8BVF INC/IL 2.67%
9GEODE CAPITAL MANAGEMENT, LLC 2.24%
10GV Management Company, L.L.C. 2.19%

Reported REVOLUTION MEDICINES INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

REVOLUTION MEDICINES INC. holdings and ownership disclosed for the 2024-2025 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Vanguard Group16,612,035 8.92%Form 13F, quarter ended March 31, 2025
BlackRock14,692,392 7.89%Form 13F, quarter ended March 31, 2025
Farallon Partners, L.L.C.14,225,683 7.64%Schedule 13G, filed February 9, 2026
Wellington Management11,787,921 6.33%Form 13F, quarter ended March 31, 2025
Entities affiliated with Wellington Management Group11,401,394 6.12%Proxy statement (DEF 14A), proxy filed April 29, 2025
JANUS HENDERSON GROUP PLC9,766,496 5.24%Schedule 13G, filed May 15, 2026
Baker Bros. Advisors LP9,455,357 5.08%Schedule 13G, filed February 17, 2026
Thilo Schroeder, Ph.D.7,601,087 4.08%Proxy statement (DEF 14A), proxy filed April 29, 2025
FMR (Fidelity)7,535,771 4.05%Form 13F, quarter ended March 31, 2025
State Street5,804,919 3.12%Form 13F, quarter ended March 31, 2025

Percentages above are of 186,258,206 shares outstanding, as reported by REVOLUTION MEDICINES INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At REVOLUTION MEDICINES INC.'s shareholder meeting held June 26, 2025, in the 2024-2025 proxy season, 285 asset managers reported votes on at least one of its 6 ballot items in their SEC Form N-PX filings, covering 2,315 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE… — REVOLUTION MEDICINES INC.'s filing reports the proposal as approved, with 98% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: REVOLUTION MEDICINES INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 27, 2025.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from REVOLUTION MEDICINES INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

REVOLUTION MEDICINES INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Cite this page

Proxy Votes Now, “REVOLUTION MEDICINES (RVMD) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/revolution-medicines-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.